ULCERATIVE COLITIS (UC)

This study looks at the safety and effectiveness of Velsipity tablets taken daily for up to 52 weeks by people with moderate to severe ulcerative colitis. About 553 participants will be followed in real-world medical settings. The goal is to see if the drug can help control sympt…

This study tests several new investigational drugs in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The goal is to see if these treatments are safe and can reduce gut inflammation, improve symptoms, and help the bowel heal. Participants will receive on…

This study tests a new way to treat moderate to severe ulcerative colitis by using two drugs in sequence. First, patients get a fast-acting drug (upadacitinib) together with a safer long-term drug (vedolizumab) for 8 weeks. Then they switch to just the safer drug for ongoing cont…

This study tests whether a smartphone app called SMART-IBD can help teenagers (ages 13-17) with inflammatory bowel disease (IBD) take their medications more regularly and improve their self-management skills. About 70 teens will be split into two groups: one using the full app wi…

This study tests if switching to guselkumab (Tremfya) helps people with inflammatory bowel disease (IBD) who didn't get enough relief from ustekinumab. Researchers will track symptoms, test results, and overall health for one year in 200 adults across Canada. The goal is to see i…

This study tests whether taking high-dose vitamin D3 (50,000 IU every two weeks) for 12 weeks can lower inflammation in people with moderate ulcerative colitis. Sixty adults aged 20-40 will either get vitamin D3 plus their usual treatment or a placebo plus usual treatment. Resear…

This study looks at people with ulcerative colitis whose disease is still active after trying at least two advanced medications. It compares quality of life between those who continue trying different drugs and those who choose surgery to remove the colon. The goal is to help fut…

This study tests whether adding the allergy drug desloratadine to standard treatment can reduce inflammation and symptoms in people with mild to moderate ulcerative colitis. About 44 adults will take either desloratadine or a placebo alongside their usual mesalamine therapy. The …

This study looks at whether people with ulcerative colitis (UC) who are in deep remission (no signs of inflammation) can safely reduce or stop their medication. Researchers will compare two groups: those who continue their current therapy and those who decrease or stop it. The go…

This study looks at whether teaching children and teens with inflammatory bowel disease (IBD) about ultra-processed foods (like packaged snacks and sugary drinks) can help them eat less of them. About 120 participants will complete online food diaries and receive either nutrition…

This study is a large registry that will follow 10,000 people with inflammatory bowel disease (IBD) in Germany over many years. Its goal is to collect real-world information on how well treatments work, how the disease changes over time, and how it affects patients' daily lives. …